SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q2 2024 Earnings Conference Call August 7, 2024 8:30 AM ET

Company Participants

Samantha Sandler - Senior Director of IR

Saqib Islam - CEO

Bhavesh Ashar - Chief Commercial Officer

Jim Cassidy - CMO

Frank Perier - CFO

Badreddin Edris - COO

Conference Call Participants

Anupam Rama - JPMorgan
Yaron Werber - TD Cowen
Corinne Johnson - Goldman Sachs
Peter Lawson - Barclays
Michael Schmidt - Guggenheim
Alec Stranahan - Bank of America

Operator

Good morning. My name is Gigi, and I'll be your conference operator today. I would like to welcome everyone to the SpringWorks Therapeutics Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's remarks, there will be a question-and-answer session. Please limit your questions to one. Thank you.

I will now like to hand the conference over to Samantha Sandler, Senior Director of Investor Relations at SpringWorks Therapeutics. Samantha, you may now begin the conference.

Samantha Sandler

Thank you, and good morning, everyone. Welcome to SpringWorks Therapeutics second quarter 2024 earnings conference call. This morning, we issued a press release, which outlines our financial and operational results for the second quarter. You can access the press release, as well as the slides that we will be presenting today, by going to the Investors and Media section of our website at www.springworkstx.com.

Joining me today are Saqib Islam, Chief Executive Officer, Bhavesh Ashar, Chief Commercial Officer, Dr. Jim Cassidy, Chief Medical Officer, Frank Perier, Chief Financial Officer and Dr. Badreddin Edris, Chief Operating Officer.

Before we begin, I would like to remind you that some of the statements made during the call today are forward-looking statements that are subject to a number of risks and uncertainties. This may cause our actual results to differ materially, including those described in our reports filed with the SEC. You are cautioned not to place any undue reliance on these forward-looking statements, and SpringWorks disclaims any obligation to update such statements.

I will now turn the call over to Saqib.

Saqib Islam

Thank you, Sam, and thank you all for joining this morning. I am pleased to share our second quarter results and how we are delivering on our objective to make a profound impact on the lives of patients with devastating diseases. Starting with a video for patients with desmoid tumors, we are encouraged by the strong momentum of our U.S. launch. In the second quarter of 2024, we reported $40.2 million in net product revenue. This robust and continued growth is driven by the transformative clinical benefits from OGSIVEO, high demand from patients and physicians across treatment settings, and strong commercial execution. Since our FDA approval last November, OGSIVEO has rapidly become the standard of care systemic therapy for patients with desmoid tumors.